Acquisitions20 May 2025, 03:42 pm
Senores Pharmaceuticals Acquires ANDA for Enalapril Maleate Tablets from Wockhardt
AI Summary
Senores Pharmaceuticals Limited, through its subsidiary Senores Pharmaceuticals, Inc., USA, has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt Limited. The acquisition will be funded through the Initial Public Offer (IPO) proceeds. Enalapril is indicated for the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. The market size of Enalapril Tablet in the USA was ~USD 28.60 Mn (MAT December 2024) and ~USD 109.24 Mn (MAT March 2025). Senores is a global, research-driven pharmaceutical company with a wide range of pharmaceutical products and a strong R&D capability.
Key Highlights
- Senores Pharmaceuticals acquires ANDA for Enalapril Maleate Tablets from Wockhardt
- The acquisition will be funded through the Initial Public Offer (IPO) proceeds
- Enalapril is indicated for the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction
- The market size of Enalapril Tablet in the USA was ~USD 28.60 Mn (MAT December 2024) and ~USD 109.24 Mn (MAT March 2025)
- Senores is a global, research-driven pharmaceutical company with a wide range of pharmaceutical products and a strong R&D capability